Ofirmev 2016 U.S. PROMOTIONAL AUDIT REPORT

Published July 2017 • 28 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Ofirmev through personal promotion in 2016 and how does this compare to its peer set in the Fever and Pain – NSAIDS markets?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Mallinckrodt’s depth of coverage vary within key specialties (e.g., Anesthesiology, General Surgery, Obstetrics/Gynecology, Orthopedic Surgery, Internal Medicine, and Emergency Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Ofirmev throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers for Ofirmev in 2016?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available – covering payments to more than 900,000 U.S. healthcare professionals.
• Over 21,600 paid interactions across 12,400 physicians made on behalf of Ofirmev were carefully examined to support our analysis. In addition, interaction data from 9 peer products (e.g. Caldolor, Duexis, Dyloject, Flector Patch, Pennsaid, Sprix, Voltaren Gel, Zipsor, and Zorvolex ) was leveraged to provide benchmarking and market insights.